cardiovascular outcomes glp-1 news today Risks after Discontinuation GLP-1 Studies Add to Growing

Clinicians need to be aware of the growing grey market of injectable peptide-based substances being promoted online for weight loss.

Bariatric surgery or GLP-1 medication may help patients lose weight

The studies spanned anywhere from one to four months and recorded an average weight loss of about four and a half kg

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.

Discover our extensive range

Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users